Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological Relevance of SMAD4 and RUNX3 in Patients With Resected Pancreatic Cancer.

Pancreas - 1 Apr 2025

Hirose Katsuya, Omori Yuko, Higuchi Ryota, Yamamoto Masakazu, Furukawa Toru

Abstract excerpt

OBJECTIVES: Treating pancreatic ductal adenocarcinoma (PDAC) is a major clinical challenge, owing to its poor prognosis. Understanding the underlying molecular interactions may be crucial in determining PDAC intractability. We elucidated the combinatory role of SMAD family member 4 (SMAD4) and runt-related transcription factor 3 (RUNX3) in PDAC. METHODS: Formalin-fixed and paraffin-embedded tissues were obtained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Core Binding Factor Alpha 3 Subunit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Neoplasm Recurrence, Local

Share to Pancreatectomy

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Smad4 Protein

Source

Identifiers

PMID: 40262100
DOI: 10.1097/MPA.0000000000002429

Genes

SMAD4
RUNX3
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological Relevance of SMAD4 and RUNX3 in Patients With Resected Pancreatic Cancer.PMID 40262100Read ↗

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical SignificanceSemantic proximity Read ↗

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

Two sides of the story? Smad4 loss in pancreatic cancer versus head‐and‐neck cancerSemantic proximity Read ↗

Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.Semantic proximity Read ↗

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.Semantic proximity Read ↗

Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.Semantic proximity Read ↗

Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.Semantic proximity Read ↗

Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12D/SMAD4 Co-Mutation: A Case Report and Mini-ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.